SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
ID: RFA-CA-24-022Type: Phase II
Overview

Topic

SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: SBIRPhase: Phase IIYear: 2024

Topic Link

https://www.sbir.gov/node/2625007

Additional Information

https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-022.html
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for SBIR Phase IIB Bridge Awards to accelerate the development of cancer-relevant technologies toward commercialization. This funding opportunity aims to support small business concerns (SBCs) that have previously received SBIR or STTR Phase II awards from any Federal agency. The goal is to assist applicants in pursuing the next milestone necessary to advance a promising product or service along a commercialization pathway. The focus is on cancer therapeutics, imaging technologies, diagnostics, prevention and control tools, and model systems for cancer research. The funding will prioritize projects that have secured substantial independent third-party investor funds and those that require approval from a Federal regulatory agency. The application due date is August 21, 2024, and more information can be found at the solicitation agency URL: link.

    Files
    No associated files provided.
    Similar Opportunities
    NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required). This solicitation encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials, including mechanistic studies associated with clinical trials. The program supports milestone-driven, hypothesis-driven clinical trials related to the research mission of the NIAID that address high-priority research areas. The solicitation encourages high-risk clinical studies, which involve non-routine interventions, administration of unlicensed products, or administration of licensed products for unapproved indications. Mechanistic studies are also encouraged. The funding supports the conduct, completion, and analysis of a single clinical trial, including activities such as training of study personnel, enrollment and recruitment of study subjects, data collection and management, laboratory work, study management and oversight, safety monitoring, and regulatory activities. The project duration is not specified, but the solicitation is open until January 14, 2027. The funding specifics can be found on the grants.nih.gov website.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required). This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The funding opportunity is open until September 6, 2026. For more information and to apply, visit the solicitation agency URL: link.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required). This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The funding opportunity is open until September 6, 2026. For more information and to apply, visit the solicitation agency URL: link.
    NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required). This solicitation encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials, including mechanistic studies associated with clinical trials. The program supports milestone-driven, hypothesis-driven clinical trials related to the research mission of the NIAID that address high-priority research areas. The solicitation encourages high-risk clinical studies, which involve non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged. The funding supports the conduct, completion, and analysis of a single clinical trial, including activities such as training of study personnel, enrollment and recruitment of study subjects, data collection and management, laboratory work, safety monitoring, and regulatory activities. The project duration is not specified, but the application due dates are provided. More information can be found on the grants.gov website.
    SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development. This program aims to provide additional support for later stage research and development (R&D) and product development not typically supported through Phase II or Phase IIB grants or contracts. The program is designed to bridge the funding gap between the end of the SBIR/STTR Phase II award and the commercialization stage, often referred to as the "Valley of Death." The program supports new "Type 1" applications from recipients with Phase II or IIB SBIR/STTR awards that have been active within the last 36 months. The program focuses on providing technical assistance and late stage R&D activities, such as regulatory strategy development, intellectual property strategy development, manufacturing assistance, and market research. The program also supports activities related to late stage development, including replication of key studies, optimization of manufacturing processes, animal studies, and development of clinical trial supplies. The program allows for outsourcing of work to third-party technical assistance providers, but the small business should play a substantive role in the oversight and management of the R&D activities. The program does not support clinical trials and cannot be used to pay filing fees for patents or FDA submissions. The program is open for applications until April 6, 2025, and more information can be found on the grants.gov website.
    SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development. This program aims to provide additional support for later stage research and development (R&D) and product development not typically supported through Phase II or Phase IIB grants or contracts. The program is designed to bridge the funding gap between the end of the SBIR/STTR Phase II award and the commercialization stage, often referred to as the "Valley of Death." The program supports projects that require technical assistance and R&D studies that are typically outsourced to contract research organizations (CROs), such as regulatory assistance, IND/IDE enabling studies, toxicology, manufacturing, and clinical trials. The program also supports activities important for commercialization, such as product development, market planning, market research, and costs related to license agreements and partnerships. The program is open to companies that have received Phase II or Phase IIB funding from NIH within the last 36 months. The funding specifics, project duration, and performance goals can be found in the solicitation notice on grants.nih.gov.
    SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development. This program aims to support the transition of previously funded SBIR/STTR Phase II/IIB projects to the commercialization stage by providing additional support for later stage research and development (R&D) and product development. The program is open to recipients with Phase II or IIB SBIR/STTR awards that have been active within the last 36 months. The program supports technical assistance activities such as regulatory strategy development, intellectual property strategy development, and manufacturing assistance. It also supports late stage research and development activities such as replication of key studies, optimization of manufacturing processes, and development of clinical trial supplies. The program allows for outsourcing of work to third-party technical assistance providers, but the small business should play a substantive role in the oversight and management of the R&D activities. The funding specifics and project duration can be found in the solicitation notice on grants.nih.gov.
    NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required). This solicitation aims to support Small Business Concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require Federal regulatory approval or bring complex research tools to market. The solicitation is open until September 6, 2026, and more information can be found at the provided links.
    Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required). This grant aims to support early-career scientists and health professionals interested in transitioning to a small business to gain industry experience, receive entrepreneurial training and mentorship, and advance biomedical or public health technology with commercial potential. The grant utilizes the R43/R44 SBIR Award mechanism and supports research and development efforts, as well as the employment and salaries of researchers as Program Directors/Principal Investigators overseeing the project. The grant requires the inclusion of at least one mentor and a career development plan for the PD/PI, which may include entrepreneurship training. The eligibility of the contact PD/PI is limited to scientists, engineers, and health professionals who are new to research entrepreneurship and have not independently led significant research programs. The proposed projects must pertain to the mission space of one of the participating Institutes and Centers and fall within the scope of the traditional SBIR/STTR grant mechanisms. The grant supports Phase I and Fast-Track applications and encourages diversity in the biomedical entrepreneurial workforce. The specific research priorities and areas of interest vary among the participating Institutes and Centers, such as the National Center for Complementary and Integrative Health, National Eye Institute, National Human Genome Research Institute, National Heart, Lung, and Blood Institute, and others. The grant is currently open for applications, with multiple application due dates throughout the year. More information and the full solicitation can be found at the provided links.
    NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required) topic. This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The solicitation is open until September 6, 2026, and more information can be found at the provided links.